XNYS
HAE
Market cap5.43bUSD
Oct 08, Last price
119.47USD
1D
17.46%
1Q
56.81%
Jan 2017
197.19%
Name
Haemonetics Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Related entities
Subsidiaries (2)
HAEMONETICS MANUFACTURING, INC.
HAEMONETICS S.A.
Key people
Frank Chan
Chief Operating Officer, Executive Vice President · since 2025
Michelle Basil
Executive Vice President, General Counsel · since 2017
James D'arecca
Executive Vice President, Chief Financial Officer · since 2022
Roy Galvin
Executive Vice President, Chief Commercial Officer · since 2025
Laurie Miller
Chief Human Resources Officer, Senior Vice President · since 2021
Olga Guyette
Vice President, Investor Relations & Treasury · since 2025
President, Chief Executive Officer, Director · since 2016
Independent Director · since 2017
Independent Director · since 2023
Independent Director · since 2020
Independent Director · since 2014
Independent Director · since 2021
Mark Kroll
Independent Director · since 2006
Independent Director · since 2019
Independent Chairman of the Board · since 2021
Legal address
C/O C T CORPORATION SYSTEM
155 FEDERAL STREET
STE 700
BOSTON, MA 02110
US
155 FEDERAL STREET
STE 700
BOSTON, MA 02110
US
Headquarters
125 SUMMER STREET
BOSTON, MA 02111
US
BOSTON, MA 02111
US
Previous name
LATHAM LABS, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2024‑03 | 2023‑03 | 2023‑03 | 2022‑03 | 2022‑03 | 2021‑03 | 2021‑03 | 2020‑03 | 2020‑03 | 2019‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2017‑03 | |
| Income | |||||||||||||||||
Revenues | |||||||||||||||||
Cost of revenue | |||||||||||||||||
Unusual Expense (Income) | |||||||||||||||||
NOPBT | |||||||||||||||||
NOPBT Margin | |||||||||||||||||
Operating Taxes | |||||||||||||||||
Tax Rate | |||||||||||||||||
NOPAT | |||||||||||||||||
Net income | |||||||||||||||||
Dividends | |||||||||||||||||
Dividend yield | |||||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||||
BB yield | |||||||||||||||||
| Debt | |||||||||||||||||
Debt current | |||||||||||||||||
Long-term debt | |||||||||||||||||
Deferred revenue | |||||||||||||||||
Other long-term liabilities | |||||||||||||||||
Net debt | |||||||||||||||||
| Cash flow | |||||||||||||||||
Cash from operating activities | |||||||||||||||||
CAPEX | |||||||||||||||||
Cash from investing activities | |||||||||||||||||
Cash from financing activities | |||||||||||||||||
FCF | |||||||||||||||||
| Balance | |||||||||||||||||
Cash | |||||||||||||||||
Long term investments | |||||||||||||||||
Excess cash | |||||||||||||||||
Stockholders' equity | |||||||||||||||||
Invested Capital | |||||||||||||||||
ROIC | |||||||||||||||||
ROCE | |||||||||||||||||
| EV | |||||||||||||||||
Common stock shares outstanding | |||||||||||||||||
Price | |||||||||||||||||
Market cap | |||||||||||||||||
EV | |||||||||||||||||
EBITDA | |||||||||||||||||
EV/EBITDA | |||||||||||||||||
Interest | |||||||||||||||||
Interest/NOPBT | |||||||||||||||||